Caring for lifer and health Making contributions to the health of human beings
Jinrui Beijing
Beijing Jinrui Jiye Pharmaceutical Technology Co., Ltd.
Founded in September 2020 and settled in Daxing Biomedical Base in October 2022, Beijing Jinrui Jiye Pharmaceutical Technology Co., Ltd. is an innovative R&D-focused pharmaceutical enterprise dedicated to the development of novel small-molecule therapeutics for anti-tumor and autoimmune diseases.The company owns domestically leading and internationally competitive integrated platforms including a liposome R&D & manufacturing platform and a natural medicine research platform (both at Jinrui Jiye Western R&D Center), a small-molecule drug discovery platform (Beijing), and a clinical research center (Beijing). Four clinical programs are currently under development.
Small-Molecule Drug Discovery Platform
The platform conducts full in-house development spanning small-molecule design, chemical synthesis through to IND filing. Multiple proprietary Class 1 new drug candidates developed by the company have advanced into clinical trials. Backed by a high-caliber technical team with robust capabilities in new drug project initiation and abundant regulatory resources, the specialized regulatory team keeps abreast of evolving review policies and regulatory requirements to accelerate IND clearance and subsequent NDA approval procedures.
Clinical Research Center
Led by senior clinical experts, the core team of the Clinical Research Center consists of professionals with over a decade of clinical research and operational experience. In addition, a panel of distinguished industry experts led by academicians serves as the company’s scientific advisory board, providing comprehensive guidance to ensure professional execution and regulatory compliance of clinical trials and facilitate streamlined progression of projects toward NDA submission.
Jinrui Western R&D Center (Chengdu West Hi-Tech)
Jinrui Jiye Western R&D Center specializes in the R&D of innovative small-molecule drugs for the treatment of various advanced malignant tumors, encompassing a natural pharmaceutical research platform and a liposome development platform.
Liposomal Formulation R&D and Manufacturing Platform
With over a decade of technological development and experience accumulation, Jinrui’s liposome R&D platform has mastered core technologies covering the full industrial chain and built an outstanding R&D & production team. Led by high-caliber researchers with advanced academic credentials, the team consists of seasoned R&D specialists and skilled frontline technicians boasting comprehensive industry expertise across diverse fields. Multiple liposome-based pharmaceutical products have been successfully developed to date. Notably, Honokiol Liposome for Injection is currently undergoing Phase II clinical trials.
Natural Medicine R&D Platform
✦ Natural Drug Extraction PlatformEquipped with a GMP-compliant workshop adopting counter-current chromatography and supercritical fluid extraction technologies, the platform enables large-scale production of pharmaceutical-grade extracts and bioactive monomers, including honokiol, magnolia bark extract, ligustilide, chuanxiong rhizome extract, gastrodin and other ingredients.
✦ Bioactive Substance Screening PlatformScreening is performed via in vitro assays (enzymatic and cellular levels) and in vivo animal models (nematode, fruit fly, zebrafish and mouse). A variety of bioactive natural small-molecule compounds have been identified on this platform for subsequent further pharmacological assessment.
Jinrui Jiye Production Base (Mianzhu)
✦ Mianzhu-based API Production Workshop of Sichuan Jinrui: Capable of large-scale manufacturing of pharmaceutical-grade extracts and bioactive monomers including honokiol, magnolia bark extract, ligustilide, chuanxiong rhizome extract and gastrodin, with honokiol purity exceeding 99.5%. The workshop covers a construction area of 2,500 square meters.
✦Mianzhu Liposome Production Base (Under Construction): Phase II construction of the formulation plant was initiated in 2025 to accommodate production capacity demands over the next decade.
✦ Sinopharm Xinlibang Formulation Workshop: Core production equipment is independently innovated and in-house designed; complying with GMP specifications and already in commercial production. The workshop undertakes contract R&D and toll manufacturing services for diverse small-molecule liposomal formulations.
